PMDA drug package insert
エムプリシティ点滴静注用300mg
PMDA Prescription drug · ブリストル・マイヤーズ スクイブ株式会社 · package insert Apr 17, 2026
Key facts
| Brand names | エムプリシティ点滴静注用300mg, エムプリシティ点滴静注用400mg |
|---|---|
| Nonproprietary names | エロツズマブ（遺伝子組換え） |
| Companies | 製造販売元／ブリストル・マイヤーズ スクイブ株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤; ヒト化抗ヒトSLAMF7モノクローナル抗体 |
| Therapeutic category codes | 874291 |
| YJ codes | 4291434D1020, 4291434D2027 |
| Approval numbers | 22800AMX00698000, 22800AMX00699000 |
| Package insert edition | 第4版 |
| Package insert date | Apr 17, 2026 |
| PMDA document key | 670605_4291434D1020_1 |
| PMDA company code | 670605 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: